July 5th 2025
Collaborations between academic and community cancer centers enhance access to care, with success in acute myeloid leukemia and precision oncology.
Personalized CLL Therapy With MRD Guidance Improves Survival Outcomes
February 6th 2025A study showed that using measurable residual disease (MRD) to guide ibrutinib-venetoclax therapy significantly improved progression-free survival in chronic lymphocytic leukemia (CLL) compared with standard chemoimmunotherapy.
Read More
Development of Multipayer Claims-Based Emergency Department Episodes of Care
Thirty-day episodes of care initialized by emergency department visits can inform future quality improvement efforts.
Read More
Balancing Risks and Opportunities of Utilizing AI in Health Data: Carrie Kozlowski
February 5th 2025In this interview, chief operating officer and cofounder of Upfront Healthcare, Carrie Kozlowski, OT, MBA, discusses the integration of artificial intelligence (AI) in health care, emphasizing both opportunities and risks.
Watch
Physician Gaps in Genetic Testing Knowledge May Impact Ovarian Cancer Care
February 5th 2025While genetic testing rates for advanced ovarian cancer have increased, gaps in physician understanding and confidence in interpreting results may limit optimal biomarker-driven treatment and patient access to genetic counseling.
Read More
Weight Fluctuation Threatens Kidney Health in Type 1 Diabetes
February 4th 2025Chronic kidney disease has been linked to yo-yo dieting (also known as body-weight cycling) in the general population, which interested investigators in potential links between these weight fluctuations and increased risk of renal events among a population with type 1 diabetes.
Read More
Optimizing Episodic Migraine Care: ACP’s Latest Treatment Guidance
February 3rd 2025With historical data showing migraine to be underdiagnosed and undertreated, new guidance from the American College of Physicians (ACP) encompasses 3 recommendations on treating episodic migraine in adult patients in the outpatient setting.
Read More
FDA Expands Semaglutide Use for CV, Kidney Risks in T2D, CKD
January 28th 2025The latest semaglutide (Ozempic; Novo Nordisk) approval is set to tackle a major need for patients with both type 2 diabetes (T2D) and chronic kidney disease (CKD), addressing their cardiovascular (CV) and kidney disease risks.
Read More